Mortality Effects of Prolonged Hemoperfusion Therapy Using a Polymyxin B-Immobilized Fiber Column for Patients with Septic Shock : A Sub-Analysis of the DESIRE Trial
© 2018 S. Karger AG, Basel..
BACKGROUND/AIMS: The optimal duration of hemoperfusion therapy with a polymyxin B-immobilized fiber column has not yet been verified.
METHODS: This analysis examined whether hemoperfusion therapy with a polymyxin B-immobilized fiber column lasting longer than 2 h (prolonged polymyxin) improved outcomes for patients with septic shock compared to 2-h polymyxin therapy (sub-analysis of data from the DESIRE trial).
RESULTS: The 2-h and prolonged polymyxin groups contained 22 and 14 patients, respectively. Both groups had similar characteristics. The polymyxin duration per session in the prolonged polymyxin group was significantly longer (median, 5.5 h) than in the 2-h polymyxin group (p < 0.01). The 28-day mortality rate was significantly higher in the 2-h polymyxin group (7, 31.8%) than in the prolonged polymyxin group (0, 0%; p = 0.019).
CONCLUSION: Prolonged polymyxin therapy might be associated with better clinical outcomes than 2-h polymyxin therapy in patients with septic shock. Video Journal Club "Cappuccino with Claudio Ronco" at http://www.karger.com/?doi=491744.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Blood purification - 46(2018), 4 vom: 11., Seite 309-314 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kawazoe, Yu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical Trial |
|---|
| Anmerkungen: |
Date Completed 07.03.2019 Date Revised 07.03.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1159/000491744 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM287384462 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM287384462 | ||
| 003 | DE-627 | ||
| 005 | 20231225053906.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000491744 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0957.xml |
| 035 | |a (DE-627)NLM287384462 | ||
| 035 | |a (NLM)30099437 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kawazoe, Yu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mortality Effects of Prolonged Hemoperfusion Therapy Using a Polymyxin B-Immobilized Fiber Column for Patients with Septic Shock |b A Sub-Analysis of the DESIRE Trial |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.03.2019 | ||
| 500 | |a Date Revised 07.03.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2018 S. Karger AG, Basel. | ||
| 520 | |a BACKGROUND/AIMS: The optimal duration of hemoperfusion therapy with a polymyxin B-immobilized fiber column has not yet been verified | ||
| 520 | |a METHODS: This analysis examined whether hemoperfusion therapy with a polymyxin B-immobilized fiber column lasting longer than 2 h (prolonged polymyxin) improved outcomes for patients with septic shock compared to 2-h polymyxin therapy (sub-analysis of data from the DESIRE trial) | ||
| 520 | |a RESULTS: The 2-h and prolonged polymyxin groups contained 22 and 14 patients, respectively. Both groups had similar characteristics. The polymyxin duration per session in the prolonged polymyxin group was significantly longer (median, 5.5 h) than in the 2-h polymyxin group (p < 0.01). The 28-day mortality rate was significantly higher in the 2-h polymyxin group (7, 31.8%) than in the prolonged polymyxin group (0, 0%; p = 0.019) | ||
| 520 | |a CONCLUSION: Prolonged polymyxin therapy might be associated with better clinical outcomes than 2-h polymyxin therapy in patients with septic shock. Video Journal Club "Cappuccino with Claudio Ronco" at http://www.karger.com/?doi=491744 | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Endotoxin | |
| 650 | 4 | |a Hemoperfusion therapy | |
| 650 | 4 | |a Optimal duration | |
| 650 | 4 | |a Septic shock | |
| 650 | 4 | |a Toraymyxin | |
| 650 | 7 | |a Polymyxin B |2 NLM | |
| 650 | 7 | |a J2VZ07J96K |2 NLM | |
| 700 | 1 | |a Sato, Tetsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Miyagawa, Noriko |e verfasserin |4 aut | |
| 700 | 1 | |a Yokokawa, Yuta |e verfasserin |4 aut | |
| 700 | 1 | |a Kushimoto, Shigeki |e verfasserin |4 aut | |
| 700 | 1 | |a Miyamoto, Kyohei |e verfasserin |4 aut | |
| 700 | 1 | |a Ohta, Yoshinori |e verfasserin |4 aut | |
| 700 | 1 | |a Morimoto, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamura, Hitoshi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood purification |d 1993 |g 46(2018), 4 vom: 11., Seite 309-314 |w (DE-627)NLM012656127 |x 1421-9735 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2018 |g number:4 |g day:11 |g pages:309-314 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000491744 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2018 |e 4 |b 11 |h 309-314 | ||